Kinfo
BioAge Labs, Inc. logo

BioAge Labs, Inc.

BIOANASDAQHealthcare·US · USD
$11.45
-0.27 (-2.30%)
Prices as of August 10, 2026 · market closed

Price

Key statistics

Valuation
Market cap525.52M USD
Enterprise value222.00M USD
Trailing P/E1.38
Forward P/E-4.97
PEG ratio-0.42
Price / sales51.95
Price / book1.43
Profitability
Gross margin0.00%
Operating margin-1196.78%
Profit margin0.00%
Return on assets-18.47%
Return on equity-28.21%
Income (TTM)
Revenue10.36M USD
Gross profit-77.43M USD
EBITDA-106.02M USD
Net income-94.46M USD
Diluted EPS-$2.39
Rev. growth (YoY)1.60%
Balance sheet
Total cash318.74M USD
Total debt2.83M USD
Debt / equity0.76
Current ratio17.19
Book value / share$8.19
Cash flow (TTM)
Operating cash flow-87.60M USD
Levered free cash flow-58.07M USD
Shares & price
Shares outstanding45.78M
Float35.89M
Held by institutions84.94%
Beta0.00
50-day MA$19.82
200-day MA$16.67
52-week high$25.96
52-week low$4.33
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-05-0.62-0.58+6.45%2026-05-08-0.63-0.52+17.46%2026-04-150.500.53+6.00%2026-03-24-0.67-0.72−7.46%2026-02-033.323.33+0.30%
About BioAge Labs, Inc.

BioAge Labs Inc. is a biotechnology company focused on discovering and developing therapies that can enhance the human lifespan and address age-related diseases. By leveraging advanced technologies like artificial intelligence and genomics, BioAge Labs aims to pinpoint key molecular drivers of aging. Its approach involves identifying biological pathways that extend healthy lifespan, then discovering compounds that can influence these pathways to develop innovative treatments for age-associated conditions such as cancer, cardiovascular diseases, and metabolic disorders. BioAge Labs conducts research that spans various stages, from preclinical studies to early-stage clinical trials, frequently collaborating with leading scientific institutions and pharmaceutical partners. Operating within the biopharmaceutical industry, the company's work significantly impacts healthcare and wellness sectors by potentially altering age-related disease progression and improving quality of life for aging populations. As part of the burgeoning field of biotechnology focusing on longevity, BioAge Labs holds a notable place in the financial market by engaging in an area of medicine that combines cutting-edge bioinformatics with traditional biopharmaceutical research and development.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Kristen Fortney Ph.D.
Employees
60
Headquarters
EmeryVille, CA, United States

Frequently asked questions about BioAge Labs, Inc.